Author:
Champiat S.,Lambotte O.,Barreau E.,Belkhir R.,Berdelou A.,Carbonnel F.,Cauquil C.,Chanson P.,Collins M.,Durrbach A.,Ederhy S.,Feuillet S.,François H.,Lazarovici J.,Le Pavec J.,De Martin E.,Mateus C.,Michot J.-M.,Samuel D.,Soria J.-C.,Robert C.,Eggermont A.,Marabelle A.
Reference88 articles.
1. Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209 – 032. ASCO 2015;Antonia;J Clin Oncol,2015
2. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015
3. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. ASCO 2015;Plimack;J Clin Oncol,2015
4. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): preliminary results from KEYNOTE-012 expansion cohort. ASCO 2015;Seiwert;J Clin Oncol,2015
5. Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. ASCO 2015;Segal;J Clin Oncol,2015
Cited by
755 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献